UAB To Test Potential COVID-19 Vaccine
By BirminghamWatch
The University of Alabama at Birmingham and the biopharmaceutical company Altimmune Inc. will test a potential vaccine for COVID-19, the university announced today.
Testing of the vaccine, AdCOVID, which was developed by the company based in Gaithersburg, Maryland, will begin in mice during the second quarter of this year. That phase of testing, designed to show the immune response to the drug in mice, is expected to take one to two months, UAB said in announcing the collaboration.
The vaccine is given in a single dose of intranasal spray, UAB said. If results of the tests in mice warrant, Altimmune could launch a Phase 1 human safety trial during the third quarter of this year.
The announcement by UAB said Altimmune “has significant experience in the development of intranasal vaccine candidates for respiratory pathogens, including a seasonal and pandemic influenza vaccine and a vaccine for inhalation anthrax.”
“We are eager to collaborate with Altimmune on this important project,” said Frances E. Lund, the Charles H. McCauley Professor and Chair for the UAB Department of Microbiology. “The expertise and infrastructure at UAB will be invaluable to the rapid progression of this vaccine into clinical studies.
Lund said six labs at UAB will work on the project.
Vipin K. Garg, president and CEO of Altimmune, cited UAB’s role in research in virology and immunology. He said the company was founded through a technology license from UAB in 1997.
“It is critical that the biotechnology industry and academic institutions work together to prevent the further spread of COVID-19, and UAB is an ideal partner to support us in this effort,”Garg said.
UAB also has extensive experience in conducting clinical studies of vaccines and has participated in studies sponsored by the Vaccine Evaluation and Trial Unit, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
The vaccine being tested “will activate mucosal and cellular immune responses, as well as a strong antibody response in the blood,” the announcement said.
“If the AdCOVID vaccine candidate is as stable as Altimmune’s influenza and anthrax vaccines candidates, that may allow inexpensive and efficient distribution of the millions of doses needed for widespread vaccination of populations,” the statement said.
RFK Jr. names new slate of vaccine advisers after purging CDC panel
Two days after firing vaccine experts who help set the nation's immunization policies, HHS Secretary Robert F. Kennedy Jr. has picked eight successors for the CDC panel.
Leaders of ‘orgasmic meditation’ company were convicted of forced labor: What to know
OneTaste billed itself as a sexual wellness business centered on "orgasmic meditation." Prosecutors said former leaders subjected victims to sexual and emotional abuse.
LA braces for Marines as California sues to stop military involvement
With the federalized National Guard deployed against the state's wishes and the Marines on the way to L.A., there are growing concerns about the policing role of the military.
In Miami, deportations are raising concerns among Cuban-Americans
South Florida's Cuban-American community supports President Trump, but some members are uneasy with his immigration policies. "I'm not for deporting people without criminal records."
Performers and video game companies reach deal that ends nearly year-long strike
Performers who do stunt and voice work for video games went on strike in July after reaching a stalemate in negotiations over how companies can use A.I. in game development.
Trump’s EPA plans to repeal climate pollution limits on fossil fuel power plants
The Trump administration plans to get rid of all limits on climate-warming pollution from the nation's fossil fuel power plants. Fossil fuel interests hailed the proposal, which likely faces legal challenges from environmental groups.
